SCHEMBL13840434

SCHEMBL13840434

CCS(=O)(=O)NCCCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 6/20 0.56
ALDH1A1 P00352 3/20 0.50
TBXA2R P21731 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ADRA1A P35348 1/20 0.48
AKR1B1 P15121 1/20 0.48
PRMT1 Q99873 1/20 0.47
GPR84 Q9NQS5 6/20 0.46
PPARG P37231 6/20 0.46
PPARD Q03181 6/20 0.46
PPARA Q07869 6/20 0.46
HDAC11 Q96DB2 5/20 0.46
TSHR P16473 4/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
PTPN1 P18031 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609321 0.98 FABP4 (0.54) FABP4ALDH1A1TBXA2RMEN1KMT2A
SCHEMBL606553 0.98 FABP4 (0.54) FABP4ALDH1A1TBXA2RMEN1KMT2A
SCHEMBL31522339 0.85 GPR84 (0.50) FABP4ALDH1A1TBXA2RMEN1KMT2A
SCHEMBL9266535 0.85 ALDH1A1 (0.44) FABP4ALDH1A1MEN1KMT2AAKR1B1
SCHEMBL31522322 0.83 GPR84 (0.53) FABP4ALDH1A1MEN1KMT2AAKR1B1
SCHEMBL3165524 0.82 MEN1 (0.43) FABP4MEN1KMT2APPARA
SCHEMBL3170341 0.82 MEN1 (0.43) FABP4MEN1KMT2APPARA
SCHEMBL7416799 0.81 FABP4 (0.58) FABP4ALDH1A1TBXA2RADRA1AAKR1B1
Adipic Acid SCHEMBL28253795 0.79 LMNA (0.65) FABP4ALDH1A1MEN1KMT2AADRA1A
SCHEMBL4004131 0.79 FABP4 (0.56) FABP4ALDH1A1TBXA2RMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534892-B2 Sulfonamide compound SHIONOGI & CO., LTD. (JP) 2009-05-19 US disclosed
US-7534892-B2 Sulfonamide compound SHIONOGI & CO., LTD. (JP) 2009-05-19 US disclosed
US-20070287710-A1 Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent SHIONOGI & CO., LTD. (JP) 2007-12-13 US disclosed
US-20070287710-A1 Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent SHIONOGI & CO., LTD. (JP) 2007-12-13 US disclosed
EP-1760073-A1 SULFONAMIDE COMPOUND SHIONOGI & CO., LTD. (JP) 2007-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287710-A1 Piperidinediyl-containing sulfonamide; NPY Y5 receptor antagonist activity; antiobesity agent or anorectic agent NPY5R, NPY1R, NPY2R FABP4 472/4885ALDH1A1 3413/4885TBXA2R 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.